Related Experiment Video
Updated: Aug 24, 2025
Intramyocardial Cell Delivery: Observations in Murine Hearts
Published on: January 24, 2014
Immunomodulatory Cell Therapy Using αGalCer-Pulsed Dendritic Cells Ameliorates Heart Failure in a Murine Dilated
Masataka Ikeda1,2,3, Tomomi Ide1,2,3, Shouji Matsushima1,2
1Department of Cardiovascular Medicine (M.I., T.I., S.M., S.I., K.O., A.I., T.T., M.S., K. Abe, M.S., A.H., K.O., H.T.), Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
Insights
Invariant natural killer T (iNKT) cell activation using α-galactosylceramide-pulsed dendritic cells (αGCDCs) shows promise for treating dilated cardiomyopathy (DCM). This immunomodulatory cell therapy improved heart function and survival in DCM mice.
Area of Science:
- Immunology
- Cardiology
- Cell Therapy
Background:
- Dilated cardiomyopathy (DCM) is a severe heart condition often linked to immune system dysfunction.
- Invariant natural killer T (iNKT) cells are known to be beneficial in ischemic heart disease, but their role in non-ischemic DCM is unclear.
- Developing effective methods for iNKT cell activation in humans is crucial for potential therapies.
Purpose of the Study:
- To investigate the efficacy of iNKT cell activation in a mouse model of DCM.
- To explore the therapeutic potential of α-galactosylceramide-pulsed dendritic cells (αGCDCs) for DCM.
- To elucidate the molecular mechanisms behind the therapeutic effects of αGCDCs in DCM.
Main Methods:
- Dendritic cells were pulsed with α-galactosylceramide ex vivo to create αGCDCs.
- DCM mice with a specific genetic mutation (troponin TΔK210/ΔK210) were treated with αGCDCs.
- Therapeutic effects were assessed by measuring survival, cardiac function (left ventricular ejection fraction), fibrosis, and molecular signaling pathways (TGF-β, Angpt1, IFNγ).
Main Results:
- αGCDC treatment increased iNKT cell numbers and prolonged survival in DCM mice.
- Cardiac function improved, and interstitial fibrosis was reduced in treated mice.
- Mechanisms involved suppression of TGF-β signaling, reduced fibrotic gene expression, and restoration of vasculature via increased Angpt1 expression.
Conclusions:
- Immunomodulatory cell therapy using αGCDCs represents a novel therapeutic strategy for heart failure in DCM.
- αGCDCs effectively activate iNKT cells, offering a potential treatment for non-ischemic cardiomyopathy.
- The study highlights the therapeutic potential of targeting iNKT cells in DCM through dendritic cell-based immunotherapy.
Background:
Dilated cardiomyopathy (DCM) is a life-threatening disease, resulting in refractory heart failure. An immune disorder underlies the pathophysiology associated with heart failure progression. Invariant natural killer T (iNKT) cell activation is a prospective therapeutic strategy for ischemic heart disease. However, its efficacy in nonischemic cardiomyopathy, such as DCM, remains to be elucidated, and the feasible modality for iNKT cell activation in humans is yet to be validated.
Methods:
Dendritic cells isolated from human volunteers were pulsed with α-galactosylceramide ex vivo, which were used as α-galactosylceramide-pulsed dendritic cells (αGCDCs). We treated DCM mice harboring mutated troponin TΔK210/ΔK210 with αGCDCs and evaluated the efficacy of iNKT cell activation on heart failure in DCM mice. Furthermore, we investigated the molecular basis underlying its therapeutic effects in these mice and analyzed primary cardiac cells under iNKT cell-secreted cytokines.
Results:
The number of iNKT cells in the spleens of DCM mice was reduced compared with that in wild-type mice, whereas αGCDC treatment activated iNKT cells, prolonged survival of DCM mice, and prevented decline in the left ventricular ejection fraction for 4 weeks, accompanied by suppressed interstitial fibrosis. Mechanistically, αGCDC treatment suppressed TGF (transforming growth factor)-β signaling and expression of fibrotic genes and restored vasculature that was impaired in DCM hearts by upregulating angiopoietin 1 (Angpt1) expression. Consistently, IFNγ (interferon gamma) suppressed TGF-β-induced Smad2/3 signaling and the expression of fibrotic genes in cardiac fibroblasts and upregulated Angpt1 expression in cardiomyocytes via Stat1.
Conclusions:
Immunomodulatory cell therapy with αGCDCs is a novel therapeutic strategy for heart failure in DCM.
